Fuji Pharma Co

Fuji Pharma Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Fuji Pharma Co (4554.T) as of Oct 18, 2026 is 127.33 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 22.34 % — a change of 470.08% (higher).

FCF Conversion

127.33 %

YoY

470.08%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Fuji Pharma Co is 2025 127.33 % . FCF Conversion Rate (FCF/EBITDA) of Fuji Pharma Co was 2024 22.34 % . It decreases by 470.08% higher compared to the previous year.

The Fuji Pharma Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
69.01 JPY
Jan 1, 2019
180.08 JPY
Jan 1, 2020
151.32 JPY
Jan 1, 2021
86.23 JPY
Jan 1, 2022
-485.02 JPY
Jan 1, 2023
-57.64 JPY
Jan 1, 2024
22.34 JPY
Jan 1, 2025
127.33 JPY
The Fuji Pharma Co FCF Conversion history
YEARFCF ConversionYoY
127.33 %+470.08%
22.34 %-138.75%
-57.64 %-88.12%
-485.02 %-662.50%
86.23 %-43.02%
151.32 %-15.97%
180.08 %+160.95%
69.01 %+29.36%
53.35 %-48.66%
103.92 %-335.53%
-44.12 %-154.64%
80.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fuji Pharma Co Stock analysis

What does Fuji Pharma Co do? Fuji Pharma Co Ltd is a Japanese company specializing in the healthcare industry. The company was founded in 2001 and is headquartered in Tokyo, Japan. It is listed on the Tokyo Stock Exchange and employs over 1,000 employees. Fuji Pharma's business model is to provide its customers with innovative and high-quality products that contribute to improving health and well-being. The company specializes in several business areas, including the development, manufacturing, and marketing of pharmaceutical products, production of OEM products for other companies, and manufacturing of dietary supplements and cosmetics. An important area for Fuji Pharma is the development and production of pharmaceuticals. The company ensures that its medications meet the highest requirements and international standards. This includes research and development of new products. The company has its own research department specializing in the development of medications that can be used in serious diseases such as cancer, diabetes, and cardiovascular diseases. In addition, Fuji Pharma is also involved in the production of OEM products for other companies. The company ensures the manufacture of medications and medical products for other pharmaceutical companies, meeting the highest quality standards and customer requirements. Fuji Pharma is proud to be a trusted partner for its customers and provides its services according to the requirements of its customers. In addition to these two divisions, Fuji Pharma also produces dietary supplements and cosmetics for the domestic and international markets. These products are designed for consumers who want to improve their health and well-being. The company places great emphasis on the development of natural and safe ingredients for its products and ensures the highest standards of quality and safety. Fuji Pharma has also specialized in the Japanese market for medical devices, particularly in the field of home respiratory devices. The company has developed a new generation of respiratory therapy devices that are safe and easy to use, providing better well-being and quality of life for patients with respiratory diseases. In addition to its business areas, Fuji Pharma also has various products in its portfolio that are known for their quality and effectiveness. One such product is "Efil," a medication used in the treatment of erectile dysfunction disorders. The medication is available in Japan and other Asian countries and has already been used by over 200,000 patients. Fuji Pharma continuously strives to improve its research and development activities and develop new innovative products and services for the healthcare industry. The company aims to bring its products and services to the international market and satisfy its customers in Japan and worldwide. Fuji Pharma Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fuji Pharma Co stock

FCF Conversion Rate (FCF/EBITDA) of Fuji Pharma Co is 127.33 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Fuji Pharma Co changed from 22.34 % to 127.33 %, representing a 470.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Fuji Pharma Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Fuji Pharma Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Fuji Pharma Co

All Key Metrics — Fuji Pharma Co